Veeva Systems announces new CRO partnership program to support growing trends in eTMF outsourcing and cloud adoption
Contract research organizations (CROs) play an integral role in clinical trials, and have emerged as crucial providers of trial master file (TMF) services. Veeva Systems’ new partnership program enables CROs to efficiently deliver electronic TMF (eTMF) services in the cloud without being saddled with technology administration. Veeva’s new program provides CRO partners with Vault eTMF training, support, and implementation services as well as ongoing collaboration on business development. Advanced Clinical selected Veeva Vault eTMF for its client trials and becomes a charter member of the Veeva Vault eTMF CRO Partnership Program.
Advanced Clinical is a global, clinical outsourcing organization that offers full service CRO, functional service provider (FSP), and strategic staffing solutions. A recognized market leader, Advanced Clinical has performed over 220 studies worldwide. “A cloud-based eTMF gives us and our clients a strategic advantage,” said Julie Ross, Executive Vice President at Advanced Clinical. “We can speed document collection from start-up through trial close, and our clients get the visibility they need throughout the entire study.”
With a cloud-based eTMF, CROs easily give sponsors access to their eTMFs, yet control exactly what they see and when. Advanced Clinical, for example, configured Vault eTMF to give sponsors access to the final, approved versions of documents, while enabling them to view comprehensive reports on TMF completeness. The content management workflows in Vault eTMF will help Advanced Clinical automate some of its most resource-intensive processes, support compliance, and dramatically reduce costs around document exchange.
Through the Veeva CRO Partnership Program, Advanced Clinical received expert training and implementation support, and is prepared to deploy Vault eTMF for new and existing studies. Going forward, Advanced Clinical will receive regular health checks and training on system updates. As a CRO partner, they benefit from ongoing strategy sessions and Veeva’s marketing outreach.
Advanced Clinical will leverage Vault eTMF for studies of increasing size, complexity, and global reach. “When we surveyed the marketplace, we found that most eTMFs are built on dated infrastructures and can’t keep up,” Ross said. “We chose Vault eTMF because it is a true cloud application that delivers the innovation and anytime-anywhere accessibility to serve our clients today and in the future.”
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.